Akash Jaiswal

Akash Jaiswal

Auto-generated profile, based on publicly available information

Akash Jaiswal

Galgotias College of Engineering and Technology,Department of Electronics and Communication Engineering,Gautam Buddha Nagar,India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Primary Care & Community Health
Verified
Journal Article
Open access
VJVikash Jaiswal
Vikash Jaiswal
GNGaurav Nepal
Gaurav Nepal
PDPatricia Dijamco
Patricia Dijamco
AIAngela Ishak
Angela Ishak
MDMehak Dagar
Mehak Dagar
AJAkash Jaiswal
Akash Jaiswal
Introduction: COVID-19 vaccines became available after being carefully monitored in clinical trials with safety and efficacy on the human body. However, a few recipients developed unusual side effects, including cerebral venous sinus thrombosis (CVST). We aim to systematically review the baseline features, clinical characteristics, treatment, and outcomes in patients developing CVST post-COVID-19 vaccination. Methods: This study was conducted according to the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) 2020 guideline. Investigators independently searched PubMed, Embase, and Google Scholar for English language articles published from inception up until September 10, 2021, reporting the incidence of CVST post-COVID-19 vaccines. We analyzed CVST patients’ baseline data, type of vaccines, clinical findings, treatment, and outcomes. Our systematic review process yielded patient-level data. Result: The final analysis included 25 studies that identified 80 patients who developed CVST after the COVID-19 vaccination. Of the 80 CVST cases, 31 (39.24%) patients died. There was no significant relationship between mortality and age ( P = .733), sex ( P = .095), vaccine type ( P = .798), platelet count ( P = .93), and comorbidities such as hypertension ( P = .734) and diabetes mellitus ( P = .758). However, mortality was associated with the duration of onset of CVST symptoms after vaccination ( P = .022). Patients with CVST post-COVID-19 vaccination were more likely to survive if treated with an anticoagulant ( P = .039). Patients who developed intracranial hemorrhage ( P = .012) or thrombosis in the cortical vein ( P = .021) were more likely to die. Conclusion: COVID-19 vaccine-associated CVST is associated with high mortality rate. Timely diagnosis and management can be lifesaving for patients.

20 May 2022
Verified
Conference Paper
Closed access
AJAkash Jaiswal
Akash Jaiswal
AAAZLAN SHAH ALI
AZLAN SHAH ALI
APAshish Pandey
Ashish Pandey
RSRajneesh Singh
Rajneesh Singh
LMLakshmanan M.
Lakshmanan M.
With the advancement in the technologies, NOMA (Non-Orthogonal Multiple Access), turns out to be a great weapon in terms of 5th Generation. NOMA (Non-Orthogonal Multiple Access) provides the facilities to permit its end users to relocate their devices to grasp similar set of code and certain protocols. To predict the origin of individual signals, users’ connection gets mostly interrogated at the reception by the application of SIC (Successive Interference Cancellation). NOMA increases the spectral efficiency (SE) which helps in lowering the error rate. The major intention behind this article is to provide a basic knowledge about bit error rate by using the help of mathematical expression of closed form structure. Eventually results are obtained in accordance with the derived mathematical models to represent Bit Error Rate (BER).